# Hyperlipidemia

Manage hyperlipidemia by separating established ASCVD, severe LDL-C elevation, and risk-based primary prevention; use statins as the foundation, refine borderline decisions with coronary artery calcium, and add nonstatins when LDL-C reduction is inadequate or statins are not tolerated.

**Clinical question:** How should physicians stratify hyperlipidemia and select lipid-lowering therapy for ASCVD prevention?

Updated: 2026-09-15T22:48:55.360161+00:00

## What matters in practice
- Use high-intensity statin therapy for secondary prevention in patients with established ASCVD. [2]
- For primary prevention in adults aged 40 to 75 years with at least one cardiovascular risk factor, prescribe a statin at estimated 10-year CVD risk of 10% or greater; selectively offer one at risk of 7.5% to less than 10%. [8]
- A coronary artery calcium score of 0 can support deferring statin therapy in selected primary-prevention patients, but not when diabetes, smoking, poorly controlled hypertension, genetic dyslipidemia, elevated lipoprotein(a), or a strong family history of premature ASCVD is present. [4]
- LDL-C of at least 190 mg/dL should prompt treatment as severe hypercholesterolemia and evaluation for familial hypercholesterolemia, including family assessment and cascade screening. [13][15]
- For patients unable to take an adequate statin regimen or needing further LDL-C reduction, ezetimibe, PCSK9 inhibitors, and bempedoic acid are evidence-based nonstatin options. [6][14]

## Assign the prevention group before choosing therapy

The indication for lipid-lowering therapy is driven by ASCVD status, LDL-C severity, and estimated primary-prevention risk.

First determine whether the patient has established ASCVD. In secondary prevention, high-intensity statin therapy is recommended; this group should not be managed as risk-calculator primary prevention. [2]

For adults without known ASCVD, separate severe hypercholesterolemia (LDL-C at least 190 mg/dL) from risk-based primary prevention. The ACC/AHA framework cited in HIV guidance identifies LDL-C at least 190 mg/dL in adults aged 20 to 75 years as an indication for statin-based primary prevention, independent of calculated 10-year risk. [13]

For adults aged 40 to 75 years without ASCVD and without severe LDL-C elevation, estimate 10-year cardiovascular risk and identify dyslipidemia, diabetes, hypertension, or smoking. USPSTF recommends prescribing a statin when at least one such risk factor is present and estimated 10-year CVD risk is at least 10%; at 7.5% to less than 10%, offer a statin selectively because expected benefit is smaller. [8]

Evidence is insufficient to determine the overall balance of benefits and harms for initiating statins for primary prevention after age 75 years; make this a patient-specific decision rather than automatically extending the 40-to-75-year threshold. [8]
- Established ASCVD: initiate or maintain high-intensity statin therapy. [2]
- LDL-C at least 190 mg/dL, age 20 to 75 years: treat as severe hypercholesterolemia and assess for familial hypercholesterolemia. [13][15]
- Age 40 to 75 years with at least one risk factor and 10-year CVD risk at least 10%: prescribe statin therapy. [8]
- Age 40 to 75 years with at least one risk factor and 10-year CVD risk 7.5% to less than 10%: selectively offer statin therapy after discussing smaller expected benefit. [8]

*Treatment-entry decisions for common hyperlipidemia presentations. [2][8][13]*

| Clinical branch | Action that follows |
| --- | --- |
| Established ASCVD | Use high-intensity statin therapy for secondary prevention. [2] |
| LDL-C at least 190 mg/dL, age 20 to 75 years | Use statin-based prevention without relying on a 10-year risk estimate; evaluate for familial hypercholesterolemia. [13][15] |
| No ASCVD, age 40 to 75 years, at least one risk factor, 10-year CVD risk at least 10% | Prescribe a statin. [8] |
| No ASCVD, age 40 to 75 years, at least one risk factor, 10-year CVD risk 7.5% to less than 10% | Selectively offer a statin; expected benefit is smaller. [8] |
| No ASCVD, age older than 75 years | Individualize initiation because evidence is insufficient to define net primary-prevention benefit. [8] |

## Use coronary artery calcium when the statin decision remains uncertain

CAC is most useful when risk estimation and patient preference do not yield a clear primary-prevention decision.

When a primary-prevention statin decision remains uncertain, coronary artery calcium can reclassify risk. A CAC score of 0 may support downgrading risk and deferring statin therapy, but do not use zero CAC as a reason to defer therapy in patients who smoke, have diabetes, poorly controlled hypertension, genetic dyslipidemia such as familial hypercholesterolemia or elevated lipoprotein(a), or a strong family history of premature ASCVD. [4]

For CAC 1 to 99, ACC/AHA guidance supports statin initiation in patients aged 55 years or older. A nonzero CAC result therefore shifts a previously equivocal conversation toward pharmacotherapy, particularly in this age group. [4]
- CAC = 0: consider deferral only after excluding diabetes, active smoking, poorly controlled hypertension, genetic dyslipidemia/elevated lipoprotein(a), and strong premature-ASCVD family history. [4]
- CAC 1-99 and age at least 55 years: favor statin initiation. [4]

*CAC interpretation for statin decisions in primary prevention. [4]*

| CAC result | Interpretation | Next action |
| --- | --- | --- |
| 0 | May identify lower near-term risk, but does not negate high-risk clinical features. [4] | Consider deferring statin only if diabetes, smoking, poorly controlled hypertension, genetic dyslipidemia/elevated lipoprotein(a), and strong premature-ASCVD family history are absent. [4] |
| 1-99 | Supports atherosclerotic plaque burden; guideline rationale favors treatment at age 55 years or older. [4] | Initiate a statin in patients aged 55 years or older. [4] |

## Evaluate LDL-C at least 190 mg/dL for familial hypercholesterolemia

Marked LDL-C elevation changes both treatment urgency and family-level prevention.

Familial hypercholesterolemia is an autosomal dominant disorder of LDL metabolism affecting approximately 1 in 200 to 300 individuals. In a patient with severe LDL-C elevation, obtain family and medical history and perform physical examination as part of case identification; these elements, together with lipid measurements, are central to recognizing affected patients. [15]

Once familial hypercholesterolemia is suspected or established, pursue cascade screening of relatives. This converts an individual lipid result into a preventive intervention for first-degree and extended family members at risk of the same inherited disorder. [15]

Lifestyle measures remain appropriate but often do not achieve LDL reduction goals in familial hypercholesterolemia, so do not delay pharmacologic LDL lowering while relying on lifestyle change alone. [15]
- Ask specifically about premature ASCVD and known severe hypercholesterolemia in relatives. [15]
- Use lipid measurements, family history, medical history, and examination to identify familial hypercholesterolemia. [15]
- Offer cascade screening when familial hypercholesterolemia is identified. [15]

*Findings that should redirect management toward familial hypercholesterolemia evaluation. [13][15]*

| Finding | Clinical implication | Next step |
| --- | --- | --- |
| LDL-C at least 190 mg/dL in an adult aged 20 to 75 years | Meets a statin-treatment entry criterion and raises concern for severe inherited hypercholesterolemia. [13] | Initiate statin-based treatment and assess for familial hypercholesterolemia. [13][15] |
| Autosomal dominant familial pattern or affected relatives | Supports an inherited LDL-metabolism disorder. [15] | Expand assessment beyond the index patient with cascade screening. [15] |
| Lifestyle response inadequate for LDL lowering | Lifestyle alone is commonly insufficient in familial hypercholesterolemia. [15] | Use lipid-lowering pharmacotherapy rather than prolonged lifestyle-only management. [15] |

## Add evidence-based nonstatins when statins are inadequate or not tolerated

Statins remain first-line; nonstatins are selected for residual LDL-C elevation or clinically meaningful statin intolerance.

Statins are first-line lipid-lowering therapy because they have LDL-C-lowering efficacy, event-reduction evidence, and favorable cost-effectiveness across primary and secondary prevention. Before labeling a patient statin intolerant, determine whether any statin regimen is tolerated, because nonstatin therapy is generally used in addition to maximally tolerated statin therapy or when intolerance prevents adequate statin use. [6]

Ezetimibe, PCSK9 inhibitors, and bempedoic acid each lower LDL-C and have evidence supporting reduction in major adverse cardiovascular events in high-risk or statin-intolerant populations. Their use is most clinically relevant when ASCVD risk is high and LDL-C remains inadequately controlled with a tolerated statin regimen, or when statin adverse effects preclude an adequate regimen. [6]

Bempedoic acid is FDA-approved as an adjunct to maximally tolerated statin therapy for LDL-C lowering in patients with ASCVD or heterozygous familial hypercholesterolemia. The bempedoic acid-ezetimibe combination is also FDA-approved as an adjunct to diet and statin therapy for adults with ASCVD or heterozygous familial hypercholesterolemia who require additional LDL-C reduction. [14]

For patients with diabetes who are statin intolerant, the cited 2024 ADA guidance recommends bempedoic acid as an alternative LDL-lowering strategy to reduce cardiovascular events. [14]
- Residual LDL-C elevation despite maximally tolerated statin in high-risk disease: consider ezetimibe, a PCSK9 inhibitor, or bempedoic acid based on indication and treatment burden. [6][14]
- Statin intolerance: use an evidence-based nonstatin rather than abandoning LDL-C lowering; bempedoic acid is an FDA-approved option in ASCVD or heterozygous familial hypercholesterolemia. [14]
- Diabetes with statin intolerance: bempedoic acid is recommended by the cited ADA 2024 guidance as an alternative strategy to reduce cardiovascular events. [14]

*Nonstatin selection principles for patients needing additional LDL-C lowering. [6][14]*

| Clinical situation | Therapeutic option | Evidence-supported role |
| --- | --- | --- |
| High-risk patient with inadequate LDL-C reduction on tolerated statin | Ezetimibe, PCSK9 inhibitor, or bempedoic acid | Each is an evidence-based nonstatin option that lowers LDL-C; these therapies have MACE-reduction evidence in appropriate populations. [6] |
| ASCVD or heterozygous familial hypercholesterolemia requiring additional LDL-C reduction | Bempedoic acid | FDA-approved as adjunct to maximally tolerated statin therapy. [14] |
| ASCVD or heterozygous familial hypercholesterolemia requiring additional LDL-C reduction | Bempedoic acid plus ezetimibe | FDA-approved combination adjunct to diet and statin therapy. [14] |
| Diabetes with statin intolerance | Bempedoic acid | Recommended by cited ADA 2024 guidance as an alternative LDL-lowering strategy to reduce cardiovascular events. [14] |

## Individualize primary prevention in people with HIV

HIV can alter the risk discussion, particularly when conventional risk estimates underrepresent clinical risk.

For people with HIV aged 40 to 75 years, use ACC/AHA/Multisociety dyslipidemia guidance for statin-based primary prevention. For those younger than 40 years, there is no HIV-specific ACC/AHA recommendation; use shared decision-making informed by HIV-related risk factors and ACC/AHA risk enhancers. [10]

For a patient with HIV whose calculated risk creates uncertainty, explicitly incorporate HIV-related factors and conventional risk enhancers into the treatment discussion rather than treating a low calculated estimate as a categorical reason against statin therapy. [10]
- HIV age 40-75 years: follow ACC/AHA/Multisociety statin guidance for primary prevention. [10]
- HIV age under 40 years: individualize the decision using HIV-related risk factors, ACC/AHA risk enhancers, and shared decision-making. [10]

*Primary-prevention statin approach in people with HIV. [10]*

| Age group | Decision approach |
| --- | --- |
| 40-75 years | Follow ACC/AHA/Multisociety dyslipidemia guidance for statin therapy in primary prevention. [10] |
| Under 40 years | No HIV-specific ACC/AHA statin recommendation; individualize with HIV-related risk factors, ACC/AHA risk enhancers, and shared decision-making. [10] |

## References
1. Rosuvastatin for Primary Prevention in Older Persons With Elevated ... — annals.org — https://annals.org/aim/article-abstract/745730/rosuvastatin-primary-prevention-older-persons-elevated-c-reactive-protein-low
2. Dyslipidemia | Annals of Internal Medicine - ACP Journals — annals.org — https://annals.org/article.aspx?doi=10.7326%2FAITC201712050
3. Management of Dyslipidemia for Cardiovascular Disease Risk ... — annals.org — https://annals.org/article.aspx?articleid=2337281
4. Comparison of Transatlantic Approaches to Lipid Management: The AHA/ACC/Multisociety Guidelines vs the ESC/EAS Guidelines - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0025619620300471
5. 2017 Taiwan lipid guidelines for high risk patients — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0929664616304302
6. PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based therapies for statin-intolerant patients - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0033062023000130
7. ESC 365 - Doctor Jelena Pavlovic — esc365.escardio.org — https://esc365.escardio.org/person/457377
8. USPSTF Releases Updated Statin Guidelines For Primary Prevention of CVD - American College of Cardiology — www.acc.org — https://www.acc.org/Latest-in-Cardiology/Articles/2022/08/23/18/48/USPSTF-Releases-Updated-Statin-Guidelines-For-Primary-Prevention-of-CVD
9. USPSTF Releases Updated Statin Guidelines For Primary ... — www.acc.org — https://www.acc.org/latest-in-cardiology/articles/2022/08/23/18/48/uspstf-releases-updated-statin-guidelines-for-primary-prevention-of-cvd
10. Update on Statin Therapy as Primary Prevention of Atherosclerotic Cardiovascular Disease in People With HIV | NIH — clinicalinfo.hiv.gov — https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/statin-therapy-people-hiv
11. The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents With HIV Announces Changes to Statin Therapy Guidance | NIH — clinicalinfo.hiv.gov — https://clinicalinfo.hiv.gov/en/news/hhs-panel-antiretroviral-guidelines-adults-and-adolescents-hiv-announces-changes-statin
12. Statins for Prevention of Cardiovascular Disease in Adults — uat.ajnr.org — https://uat.ajnr.org/lookup/external-ref?access_num=10.1001%2Fjama.2015.15629&link_type=DOI
13. [PDF] Statin Therapy in People with HIV — clinicalinfo.hiv.gov — https://clinicalinfo.hiv.gov/sites/default/files/guidelines/archive/adult-adolescent-arv-statin-therapy-2024-02-27.pdf
14. Bempedoic Acid - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK594232?report=reader
15. Familial Hypercholesterolemia - Endotext - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK395572

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.